Sei Investments Co. Sells 106,987 Shares of Eli Lilly and Company $LLY

Sei Investments Co. lowered its stake in Eli Lilly and Company (NYSE:LLY) by 16.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 562,345 shares of the company’s stock after selling 106,987 shares during the quarter. Sei Investments Co.’s holdings in Eli Lilly and Company were worth $429,076,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. Douglass Winthrop Advisors LLC lifted its holdings in Eli Lilly and Company by 13.4% in the third quarter. Douglass Winthrop Advisors LLC now owns 9,752 shares of the company’s stock valued at $7,441,000 after acquiring an additional 1,154 shares during the period. LifePlan Investment Advisors Inc. grew its stake in shares of Eli Lilly and Company by 15.6% during the 3rd quarter. LifePlan Investment Advisors Inc. now owns 355 shares of the company’s stock valued at $271,000 after purchasing an additional 48 shares during the period. Magnolia Capital Advisors LLC grew its stake in shares of Eli Lilly and Company by 0.6% during the 3rd quarter. Magnolia Capital Advisors LLC now owns 2,727 shares of the company’s stock valued at $2,081,000 after purchasing an additional 15 shares during the period. RD Lewis Holdings Inc. increased its position in shares of Eli Lilly and Company by 7.9% during the 3rd quarter. RD Lewis Holdings Inc. now owns 2,872 shares of the company’s stock valued at $2,191,000 after purchasing an additional 211 shares during the last quarter. Finally, Tortoise Investment Management LLC increased its position in shares of Eli Lilly and Company by 41.3% during the 3rd quarter. Tortoise Investment Management LLC now owns 1,447 shares of the company’s stock valued at $1,104,000 after purchasing an additional 423 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

LLY has been the topic of a number of research reports. Loop Capital set a $1,200.00 price objective on shares of Eli Lilly and Company in a report on Tuesday, February 10th. Leerink Partners upped their target price on shares of Eli Lilly and Company from $1,234.00 to $1,296.00 and gave the company an “outperform” rating in a report on Thursday, February 5th. Rothschild & Co Redburn lifted their price target on shares of Eli Lilly and Company from $775.00 to $830.00 and gave the stock a “neutral” rating in a research note on Monday, January 26th. Royal Bank Of Canada assumed coverage on shares of Eli Lilly and Company in a research report on Tuesday, February 24th. They set an “outperform” rating and a $1,250.00 price objective for the company. Finally, Daiwa Securities Group upped their price objective on Eli Lilly and Company from $1,230.00 to $1,250.00 and gave the stock a “buy” rating in a research note on Wednesday, February 18th. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, Eli Lilly and Company has an average rating of “Moderate Buy” and a consensus target price of $1,229.59.

Eli Lilly and Company Price Performance

NYSE LLY opened at $977.47 on Friday. Eli Lilly and Company has a 12 month low of $623.78 and a 12 month high of $1,133.95. The stock has a market cap of $923.54 billion, a price-to-earnings ratio of 42.59, a PEG ratio of 1.16 and a beta of 0.40. The company’s 50 day moving average is $1,039.17 and its two-hundred day moving average is $947.29. The company has a current ratio of 1.58, a quick ratio of 1.19 and a debt-to-equity ratio of 1.54.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, beating the consensus estimate of $7.48 by $0.06. The business had revenue of $19.29 billion for the quarter, compared to the consensus estimate of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company’s revenue for the quarter was up 42.6% on a year-over-year basis. During the same quarter in the previous year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. As a group, research analysts anticipate that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Key Eli Lilly and Company News

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Medicare access is expanding for Zepbound and Mounjaro, which should boost near‑term demand and reduce payer uncertainty for a large patient cohort. Eli Lilly (LLY) and CMS Expand Medicare Access to Zepbound and Mounjaro
• Positive Sentiment: Lilly announced a multibillion manufacturing build‑out in China to secure supply and capture a huge GLP‑1 market — a strategic long‑term revenue driver. Lilly to Invest $3 Billion in China to Boost Obesity Pill
• Positive Sentiment: Lilly is expanding manufacturing and partnerships in Asia (Korea $500M incubator and Japan plant expansion), diversifying capacity and helping global rollout. Eli Lilly invests $500 million in Korea’s biotech growth
• Positive Sentiment: Lilly is pushing multiple product catalysts: an orforglipron filing/launch (oral GLP‑1) and follow‑on candidates (retatrutide) that can sustain growth beyond current injectables. Will Policy Shifts Accelerate Demand for Eli Lilly’s GLP‑1 Drugs?
• Positive Sentiment: Employer Connect and LillyDirect initiatives aim to expand coverage and patient access (potential volume growth even if pricing is pressured). Lilly Employer Connect platform launch
• Neutral Sentiment: Premium share price and 5‑year outperformance have reignited stock‑split and megatrend commentary — sentiment boosters but not immediate fundamentals. Megatrends Still Matter: 3 Growth Stocks for the Next 10 Years (LLY)
• Negative Sentiment: Lilly issued warnings after detecting an unknown impurity in compounded tirzepatide mixed with vitamin B12 — a safety/regulatory concern that can drive near‑term caution and compounding‑market scrutiny. Using Obesity Drug? Eli Lilly Flags Unknown Impurity Found In Compounded Weight Loss Drugs With Vitamin B12
• Negative Sentiment: Shorter‑term technical/market‑sentiment concerns: some analysts/public pieces argue trading momentum has cooled since late 2025, which can accelerate sell‑offs after recent gains. Eli Lilly Reaching For Peak GLP‑1 Euphoria: Rotten Trading Momentum Since November
• Negative Sentiment: Lilly warned some Medicare plans or basic Part D designs might still leave patients with >$50 out‑of‑pocket costs under new CMS rules — a potential near‑term headwind to access and PR. Lilly Warns Some Medicare GLP‑1 Costs Could Exceed $50

Eli Lilly and Company Profile

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.